Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Gelderblom, Hans"'
Autor:
Lancia, Carlo, Anninga, Jakob K., Sydes, Matthew R., Spitoni, Cristian, Whelan, Jeremy, Hogendoorn, Pancras C.W., Gelderblom, Hans, Fiocco, Marta, Sub Mathematical Modeling, Mathematical Modeling
Publikováno v:
Cancer Chemotherapy and Pharmacology, 83, 951-962
Cancer Chemotherapy and Pharmacology, 83, 5, pp. 951-962
Cancer Chemotherapy and Pharmacology, 83, 951. Springer Verlag
Cancer Chemotherapy and Pharmacology, 83(5), 951-962
Cancer Chemotherapy and Pharmacology, 83, 5, pp. 951-962
Cancer Chemotherapy and Pharmacology, 83, 951. Springer Verlag
Cancer Chemotherapy and Pharmacology, 83(5), 951-962
Purpose: There is lack of consensus on the prognostic value of received high dose intensity in osteosarcoma survivorship. Many studies have not shown a clear survival benefit when dose intensity is increased. The aim of this study is to go beyond che
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc27d41c0aea26e45f8561ec58dd4f30
https://hdl.handle.net/1887/121132
https://hdl.handle.net/1887/121132
Autor:
Lunenburg, Carin A T C, Henricks, Linda M, Guchelaar, Henk-Jan, Swen, Jesse J, Deenen, Maarten J, Schellens, Jan H M, Gelderblom, Hans, Sub Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
European Journal of Cancer, 54, 40-48
European Journal of Cancer, 54, 40. Elsevier Ltd
European Journal of Cancer, 54, 40. Elsevier Ltd
5-Fluorouracil (5-FU) and capecitabine (CAP) are among the most frequently prescribed anticancer drugs. They are inactivated in the liver by the enzyme dihydropyrimidine dehydrogenase (DPD). Up to 5% of the population is DPD deficient and these patie
Autor:
Lunenburg, Carin A T C, Henricks, Linda M, Dreussi, Eva, Peters, Femke P, Fiocco, Marta, Meulendijks, Didier, Toffoli, Giuseppe, Guchelaar, Henk-Jan, Swen, Jesse J, Cecchin, Erika, Schellens, Jan H M, Gelderblom, Hans, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
European Journal of Cancer, 104, 210. Elsevier Ltd
Background Prospective DPYD genotyping prevents severe fluoropyrimidine (FP)-induced toxicity by decreasing dosages in DPYD variant allele carriers. FP dosages in chemoradiation therapy (CRT) are lower than those in other FP-containing regimens. Phar
Autor:
Lancia, Carlo, Anninga, Jakob, Spitoni, Cristian, Sydes, Matthew R., Whelan, Jeremy, Hogendoorn, Pancras C.W., Gelderblom, Hans, Fiocco, Marta, Sub Mathematical Modeling, Mathematical Modeling
Publikováno v:
BMJ Open, 9(5). BMJ Publishing Group Ltd
BMJ Open
BMJ Open, 9(5)
BMJ Open
BMJ Open, 9(5)
ObjectivesIn cancer studies, the target received dose intensity (tRDI) for any regimen, the intended dose and time for the regimen, is commonly taken as a proxy for achieved RDI (aRDI), the actual individual dose and time for the regimen. Evaluating